Pharmaceuticals

A notable trend in the Molecular Targeted Therapy Market is breakthrough progress in small molecule inhibitors improving outcomes in chemotherapy-resistant cancers

March 23, 2026March 23, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Molecular Targeted Therapy Market Projected To Become By 2030 Based On Its 2026 Valuation?

The molecular targeted therapy market size has experienced robust expansion in recent years. It is anticipated to increase from $71.64 billion in 2025 to $77.89 billion in 2026, growing at a compound annual growth rate (CAGR) of 8.7%. The expansion observed in the historic period stems from factors such as cancer genomics research, monoclonal antibody development, numerous oncology drug approvals, the proliferation of hospital oncology centers, and expanded clinical trial initiatives.

The molecular targeted therapy market is anticipated to experience substantial expansion over the next few years. It is forecast to achieve a value of $107.64 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.4%. This anticipated growth can be attributed to several factors, including the increasing development of personalized cancer treatment growth, the broader adoption of next-generation sequencing, advancements in AI-driven drug discovery, the escalating global oncology burden, and more favorable targeted therapy reimbursement. During the forecast period, significant trends are expected to include the continued expansion of precision oncology, a rise in the increased adoption of biomarker-based therapies, the proliferation of targeted cancer drug pipelines, the integration of companion diagnostics, and the growing application of combination targeted therapies.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24609&type=smp

Which Market Drivers Are Supporting The Expansion Of The Molecular Targeted Therapy Market?

The expansion of personalized medicine is set to fuel the growth of the molecular targeted therapy market. This healthcare method customizes prevention and treatment based on an individual’s genetic profile, lifestyle, and environmental factors. Its increasing prominence stems from the growing availability of genetic data, which enables treatments precisely tailored to individual genomes, leading to improved efficacy and reduced side effects. Personalized medicine aids molecular targeted therapy by analyzing a patient’s tumor for specific genetic mutations or biomarkers, facilitating the selection of therapies that directly address these abnormalities. This methodology enhances treatment precision while minimizing harm to healthy tissues. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, significantly up from 6 in 2022. Consequently, the ascent of personalized medicine is a key driver for the molecular targeted therapy market’s expansion.

What Segment Groups Are Identified Within The Molecular Targeted Therapy Market?

The molecular targeted therapy market covered in this report is segmented –

1) By Therapy Type: Monoclonal Antibodies, Small Molecule Inhibitors, Gene Therapy, Cell Therapy

2) By Mode Of Administration: Oral, Injectable, Topical, Intravenous

3) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Other Applications

4) By End-User: Hospitals, Clinics, Research Laboratories, Diagnostic Centers

Subsegments:

1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies

2) By Small Molecule Inhibitors: Tyrosine Kinase Inhibitors (TKIs), Proteasome Inhibitors, Poly Adenosine Diphosphate (ADP) Ribose Polymerase (PARP) Inhibitors, Mechanistic Target Of Rapamycin (mTOR) Inhibitors

3) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing

4) By Cell Therapy: Chimeric Antigen Receptor T-Cell Therapy, T-Cell Receptor (TCR) Therapy, Tumor-Infiltrating Lymphocytes (TILs) Therapy, Dendritic Cell Therapy

What Trends Are Advancing Progress In The Molecular Targeted Therapy Market?

Leading firms within the molecular targeted therapy sector are prioritizing the creation of sophisticated products, including small molecule inhibitors, aimed at enhancing patient results across numerous cancers and chronic illnesses. These inhibitors are minute compounds capable of readily entering cells to obstruct particular proteins responsible for disease progression. By way of illustration, in January 2025, Amgen Inc., a pharmaceutical company based in the US, unveiled Lumakras (sotorasib) in conjunction with Vectibix (panitumumab), securing endorsement from the US Food and Drug Administration (FDA), a US-based governmental body. This treatment is intended for adult individuals suffering from KRAS G12C-mutated metastatic colorectal cancer who have previously undergone fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, verified by an FDA-approved diagnostic method. The authorization was granted following the Phase 3 CodeBreaK 300 trial, wherein the combination demonstrated over double the progression-free survival compared to the standard of care studied, thereby becoming the initial targeted therapy to exhibit such an advantage in this specific chemorefractory patient group.

Which Companies Hold Significant Positions In The Molecular Targeted Therapy Market?

Major companies operating in the molecular targeted therapy market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Amgen Inc., Regeneron Pharmaceuticals, Vertex Pharmaceuticals Incorporated, Novartis AG, Incyte Corporation, Exelixis Inc., IDEAYA Biosciences Inc., Prelude Therapeutics Incorporated, Gamida Cell Ltd., Adaptimmune Therapeutics plc, Engine Biosciences Pte. Ltd., Krystal Biotech Inc., Sotio Biotech a.s., Cybrexa Therapeutics Inc.

Read the full molecular targeted therapy market report here:

https://www.thebusinessresearchcompany.com/report/molecular-targeted-therapy-global-market-report

How Is The Molecular Targeted Therapy Market Distributed Across Key Geographic Regions?

North America was the largest region in the molecular targeted therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molecular targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Molecular Targeted Therapy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24609&type=smp

Browse Through More Reports Similar to the Global Molecular Targeted Therapy Market 2026, By The Business Research Company

Targeted Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report

Cancer Immunotherapy Drug Discovery Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-drug-discovery-outsourcing-global-market-report

Advanced Therapeutics Pharmaceutical Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/advanced-therapeutics-pharmaceutical-outsourcing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795